In this study, we demonstrated that Shc3 acts as a novel binding protein of EphA2 and ErbB2 linking that activated Akt and MAPK pathways to mediate drug resistance and aggressive behavior in breast cancer. Here, EPHA2 is linked to breast carcinoma.